Quick Poll results from the June Issue of OncoFacts 2009
Bevacizumab was recently US Food and Drug Administratio (FDA) approved for what specific use in patients with glioblastoma multiforme?
| In combination with radiation post-operatively |
|
||
| In combination with radiation and temozolomide post-operatively |
|
||
| As a single agent in patients with progressive disease after prior therapy |
|
||
| In combination with irinotecan in patients with progressive disease after radiation and temozolomide |
|
Discussion
Answer: #3
On May 5, 2009, the FDA approved bevacizumab as a single agent for patients with glioblastoma, with progressive disease following prior therapy. The approval was based on objective response rates seen in 2 separate clinical trials: AVF3709g and NCI 06-C-0064E. AVF3708 was a randomized trial of previously treated glioblastoma patients who received bevacizumab with or without irinotecan every 2 weeks. All patients had received prior temozolomide and radiation. Responses were seen in 25.9% of patients who received single agent bevacizumab and the median response duration was 4.2 months. NCI 06-C-0064E enrolled 56 glioblastoma patients with disease progression after radiation and temozolomide. These patients received bevacizumab 10 mg/kg every 2 weeks until progression. The objective response rate was 19.6% and the median response duration was 3.9 months.
Full clinical trial information and prescribing information can be found at the following website:
Avastin® (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech Inc.; 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdf
* The aggregate results from this question were compiled from the responses submitted by oncologists who participated in the OncoFacts Quick Poll monthly question.